Clinical trials: Overactive Bladder, completed
Prostatitis, Cystitis, Interstitial
Linkage Analysis in Interstitial Cystitis
Urologic pelvic pain syndrome (UCPPS), variably termed painful bladder syndrome/interstitial cystitis (PBS/IC) in females and chronic prostatitis/chronic pelvic pain syndrome in men (CP/CPPS), is a chronic, debilitating clinical…
- Conditions
- Prostatitis, Cystitis, Interstitial, Urinary Bladder, Overactive, Chronic Pelvic Pain Syndrome
- Trial name
- IC (NCT00675298)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Overactive Bladder, Urinary Incontinence
Surface Nerve Stimulation Treatment for OAB in Children
The purpose of this study is to perform a randomized controlled investigation of the effect of surface nerve stimulation on functional daytime incontinence in children with OAB.
- Trial name
- NCT00282490
- Testing
- Nerve stimulator
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- University of Aarhus
Overactive Bladder
Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.
The purpose of this study is to evaluate the long term tolerability of Fesoterodine and its efficacy for overactive bladder syndrome in children.
- Trial name
- FOXY2015 (NCT02614482)
- Testing
- Fesoterodine
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- Stéphane Bolduc
Overactive Bladder Syndrome
Treatment of the Overactive Bladder Syndrome: A Delphi Study
Idiopathic overactive bladder syndrome (iOAB) is a prevalent condition in urological practice. The variability in management between specialists and between centers remains high.
- Trial name
- NCT04300400
- Testing
- Delphi questionnaire
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Ghent
Overactive Bladder, Urinary Incontinence
Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder
The objective is to evaluate the efficacy and safety of mirabegron to treat urinary incontinence in children with Overactive Bladder that are refractory and/or intolerant to antimuscarinics.
- Trial name
- Mirabegron (NCT02468830)
- Testing
- mirabegron
- Volunteers
- 58 people
- Sponsor
- CHU de Quebec-Universite Laval
Overactive Bladder, Neurogenic Detrusor Overactivity
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
The purpose of the study is to evaluate the pharmacokinetics (PK) of mirabegron oral suspension after single dose administration in children with neurogenic detrusor overactivity (NDO) or overactive bladder (OAB).
- Trial name
- NCT02526979
- Testing
- mirabegron
- Where
- 3 sites in Denmark, Poland
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Europe B.V.
Overactive Bladder
Post Marketing Survey of Vesicare in Japan
This study is to evaluate the effect of Vesicare on quality of life (QOL) in female patients.
- Trial name
- SET-Q (NCT01489709)
- Testing
- Vesicare
- Where
- 8 sites in Japan
- Volunteers
- 1,160 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder (OAB)
The Role of Urinary ATP in the Diagnosis, Treatment, and Follow-up of Children With Overactive Bladder
In this study, the investigators aim to evaluate the role of urinary ATP as a biomarker for the diagnosis, treatment, and follow-up of OAB in children for the first time in a clinical investigation, as previous research has been…
- Trial name
- NCT06785558
- Testing
- Anticholinergic therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Marmara University
Overactive Bladder, Neurogenic Detrusor Overactivity
Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder
The purpose of this study is to evaluate blood levels of solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after taking a single oral dose.
- Trial name
- NCT01539707
- Testing
- Solifenacin succinate suspension 5 mg
- Where
- 7 sites in Belgium, Canada and 5 more
- Volunteers
- 14 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Does Bladder Training Improve the Efficacy of Nerve Stimulation in Women With Refractory Overactive Bladders
Overactive Bladder (OAB) is a chronic condition defined as urgency with or without incontinence usually associated with frequency and nocturia.
- Trial name
- NCT02107820
- Testing
- Bladder Training (BT), Percutaneous Tibial Nerve stimulation
- Where
- United Kingdom
- Volunteers
- 84 people
- Sponsor
- University Hospital Plymouth NHS Trust
Urinary Bladder, Overactive
A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076
This was a 40-week study to investigate how safe and effective solifenacin solution was in treating children or adolescents with symptoms of overactive bladder (OAB), who completed study 905-CL-076 (NCT01565707).
- Trial name
- LEOPARD (NCT01655069)
- Testing
- Solifenacin succinate suspension
- Where
- 39 sites in United States, Belgium and 14 more
- Volunteers
- 148 people
- Sponsor
- Astellas Pharma Europe B.V.
Neurogenic Bladder, Detrusor Underactivity
A Comparative Analysis of Portable Bladder Scanner to Determine Age/ Volume Specific Accuracy in 0-6 Years of Children
As a part of the urodynamic studies, urinary catheterization is inserted to measure residual urine, however, it has shown to be an invasive procedure, cause urinary tract infection, and traumatic experience.
- Conditions
- Neurogenic Bladder, Detrusor Underactivity, Detrusor Overactivity
- Trial name
- NCT04543552
- Testing
- Bladder scan
- Where
- South Korea
- Volunteers
- 34 people
- Sponsor
- Seoul National University Hospital
Overactive Bladder, Incontinence, Daytime Urinary
Botulinum Neurotoxin Type A (BoNT-A) in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder (OAB)
A non-intervention cohort study on the use of Botulinum Neurotoxin Type A (BoNT-A) in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder (OAB). Primary endpoint was the reduction of urinary incontinence.
- Conditions
- Overactive Bladder, Incontinence, Daytime Urinary, Incontinence, Nighttime Urinary
- Trial name
- NCT06569342
- Testing
- Intradetrusor BoNT-A
- Where
- Denmark
- Volunteers
- 43 people
- Sponsor
- University of Aarhus
Overactive Bladder (OAB), Menopause
Effect of Vaginal Estrogen on Alterations in the Urine Microbiome of Menopausal Women With Overactive Bladder
The goal of this Pre-Post Quasi-experimental study is to investigates the effect of vaginal estrogen therapy on changes in the urinary microbiome and its association with improvement in overactive bladder (OAB) symptoms in…
- Conditions
- Overactive Bladder (OAB), Menopause, Microbiome
- Trial name
- NCT06780163
- Testing
- 17β-estradiol 10 mcg
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Mahidol University
Overactive Bladder, Pediatric Disorder
Efficacy and Mechanism of High-Dose Vitamin D Supplementation in Pediatric OAB-Dry: A Randomized Clinical Trial Integrating Urinary Myelin Basic Protein as a Theranostic Biomarker
The aim of this study is to give children with dry OAB: (1) Standard behavioral therapy combined with classical anticholinergic drugs (Solinaxine), or (2) standard behavioral therapy combined with short-term high-dose exogenous…
- Trial name
- NCT06489951
- Testing
- Solifenacin, vitamin D, Standard behavioral therapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Xing Liu
Urinary Urge Incontinence
Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Non-neurogenic urinary urge incontinence (UUI) is a common quality of life disorder that causes people to feel an "urgent" need to urinate.
- Trial name
- NCT01226706
- Testing
- Botulinum Toxins, Type A
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Saskatchewan Health Authority - Regina Area
Detrusor Hyperreflexia
Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g.
- Trial name
- NCT00224016
- Testing
- Oxybutynin
- Where
- 23 sites in United States
- Volunteers
- 57 people
- Sponsor
- Watson Pharmaceuticals
Overactive Bladder, Cardiovascular Disease
Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease
This purpose of this study is to investigate the effects of mirabegron on the cardiovascular system in patients with overactive bladder with current or a history of cardiovascular disease.
- Trial name
- NCT02570035
- Testing
- Mirabegron
- Where
- 28 sites in Japan
- Volunteers
- 316 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder, Urinary Incontinence
Programmable Timer in the Bladder Rehabilitation Treatment of OAB
The purpose of this study is to evaluate the effect of bladder rehabilitation in a non-selected group of children with idiopathic overactive bladder and to clarify whether the effect of the treatment can be increased by addition…
- Trial name
- NCT00238680
- Testing
- Bladder rehabilitation, Bladder rehabilitation with programmable timer
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Constipation
Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome
HYPOTHESIS: Is MiraLAX an effective treatment of pediatric urinary urge syndrome? OBJECTIVE: Polyethylene glycol (PEG) is common first-line therapy for urinary symptoms despite minimal evidence-based support.
- Trial name
- NCT00765557
- Testing
- MiraLAX
- Volunteers
- 138 people
- Sponsor
- University of Texas Southwestern Medical Center